Jump to content

Bio-Synthesis, Inc.: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Nchao (talk | contribs)
82 edits
No edit summary
Nchao (talk | contribs)
82 edits
No edit summary
Line 13: Line 13:
}}
}}


== Overview ==
'''Bio-Synthesis, Inc.''' (BSI) is a biotechnology company headquartered in Lewisville, Texas. It is a provider of custom and catalog peptides, custom oligos, antibodies, organic synthesis, and analytical services. Biomedical researchers worldwide in universities, biotech companies, private clinics, and government agencies use products from Bio-Synthesis, Inc. in studies ranging from PCR diagnostics to cancer research and the Human Genome Project.
'''Bio-Synthesis, Inc.''' (BSI) is a biotechnology company headquartered in Lewisville, Texas. It is a provider of custom and catalog peptides, custom oligos, antibodies, organic synthesis, and analytical services. Biomedical researchers worldwide in universities, biotech companies, private clinics, and government agencies use products from Bio-Synthesis, Inc. in studies ranging from PCR diagnostics to cancer research and the Human Genome Project.


Revision as of 21:26, 8 February 2010

Bio-Synthesis, Inc.
Company typePrivate
IndustryBiotechnology
Founded1984
HeadquartersLewisville, Texas
Key people
Miguel Castro, PhD - Founder & CEO
Jessica Castro, PhD - VP
Productscustom and catalog peptides, antibodies, organic synthesis, custom oligos, gene synthesis, large scale oligonucleotide synthesis, peptide protein sequencing, analytical services
Websitehttp://www.biosyn.com/

Bio-Synthesis, Inc. (BSI) is a biotechnology company headquartered in Lewisville, Texas. It is a provider of custom and catalog peptides, custom oligos, antibodies, organic synthesis, and analytical services. Biomedical researchers worldwide in universities, biotech companies, private clinics, and government agencies use products from Bio-Synthesis, Inc. in studies ranging from PCR diagnostics to cancer research and the Human Genome Project.

The DNA Identity Testing Center, a subsidiary of Bio-Synthesis, Inc. (BSI), works with private citizens, legal representatives, and law enforcement providing services in personal and legal paternity tests, family relationship DNA tests, immigration DNA tests, forensic DNA tests, ancestry DNA tests, and identity DNA tests.

History

Founded in 1984, Bio-Synthesis, Inc. was known as OCS Laboratories. It was the first producer of commercially available synthetic DNA and became a producer of synthetic peptides in 1985. In 1989, OCS became incorporated as Bio-synthesis, Inc. and moved its laboratories to Lewisville, TX.

In 1995, Bio-Synthesis, Inc. introduced DNA identity testing to its broad range of molecular diagnostic services. Today, the DNA Identity Testing Center of BSI uses state-of-the-art advanced techniques and automated systems to produce the most accurate DNA testing results allowed by current scientific technologies. The DNA Identity Testing Center has a dedicated staff of scientific professionals whose focus is to ensure the quality and integrity of all tests and services.

In June 2007, Bio-Synthesis, Inc. unveiled a new online software tool called Protein Lounge which brought all of the vital and necessary databases to one place. The Protein Database contained all of the necessary information for proteins, such as datasheets, reviews, signaling pathway relation, disease relation, sequences, publications and reagent links. The database offered the most comprehensive gene/protein sequence pages which have all pertinent information needed to analyze any sequence.1

In January 2008, Bio-Synthesis, Inc. announced an exclusive scientific collaboration with Dr. Dante Marciani, a world renowned expert in immune agonists. The collaboration was focused on proprietary novel glycosides that stimulate innate immunity while taking advantage of the synergistic effects between innate and adaptive immunity. In addition, the collaboration extended to proprietary compounds that down regulate Th1 immunity, an area of significance in the treatment of chronic inflammatory conditions. 2

In May 2009, Bio-Synthesis, Inc. began Mitochondrial, or MtDNA, testing and offered it commercially. The DNA Identity Testing Laboratory at Bio-Synthesis, Inc. (BSI) is currently sequencing MtDNA samples for maternal lineage and criminal investigations.3

Products & Services

  • Custom Peptide Synthesis
  • GMP Peptide Manufacturing
  • Cosmetic Peptides
  • Antibody Packages
  • Phosphospecific Antibody Production
  • Peptide Carrier Protein Conjugation
  • Antibody Purification and Labeling
  • Organic Synthesis
  • Custom Oligos (DNA, RNA, LNA, and PNA)
  • Gene Synthesis
  • Large Scale Oligonucleotide Synthesis
  • siRNA Synthesis
  • Peptide Protein Sequencing
  • Amino Acid Analysis
  • Mass Spectrometry
  • Cell Authentication Service

DNA Testing Services

  • Paternity Disputes
  • Child Custody
  • Immigration Claims
  • Inheritance
  • Adoption
  • Insurance Claims
  • Protection Against Identity Fraud
  • Establish Kinship for Benefit Claims
  • Child Safety
  • Infidelity Detection
  • Tissue Sample Verification

Accreditations, Affiliations, and Recognitions

  • American Association of Blood Banks Accredited (AABB)
  • Animal Welfare Assurance
  • U.S. Small Business Administration (SBA) Small Disadvantaged Business Certification
  • Historically Underutilized Business (HUB) Program
  • National Institutes of Health (NIH) Blanket Purchase Agreement (BPA)
  • Presenter of “Eyebrow Hairs From Cadavers as a Unique and Reliable Source of DNA for Profiling after Embalmment” poster at the Promega Meeting in October 2006.
  • Presenter of “Sibling Data Alone Cannot Always Be Used To Determine Full Sibling Relationships” poster at the Promega Meeting in October 2007.
  • Presenter of “Comparison of Three Different Blood Extraction Methods” poster at the Promega Meeting in October 2009.

Sources

  • http://www.pr.com/press-release/42613
  • http://www.pr.com/press-release/69139
  • http://www.pr.com/press-release/150301
  • Christine Zouki, Sophie Ouellet, and Janos G. Filep. “The anti-inflammatory peptides, antiflammins, regulate the expression of adhesion molecules on human leukocytes and prevent neutrophil adhesion to endothelial cells.” The FASEB Journal. Vol. 14 March 2000
  • Tomoyuki Oe, Jasbir S. Arora, Seon Hwa Lee, and Ian A. Blair. “A Novel Lipid Hydroperoxide-derived Cyclic Covalent Modification to Histone H4.” The Journal of Biological Chemistry. Vol. 278, No. 43, Issue of October 24, pp. 42098-42105, 2003.
  • Yu Lu, Patricia Bottari, Frantisek Turecek, Ruedi Aebersold, and Michael H. Gelb. “Absolute Quantification of Specific Proteins in Complex Mixtures Using Visible Isotope-Coded Affinity Tags.” Analytical Chemistry, Vol. 76, No. 14, July 15, 2004.
  • Shigeki Kobayashi, Takeshi Yamamoto, Jerome Parness and Noriaki Ikemoto. “Antibody probe study of Ca2+ channel regulation by interdomain interaction within the ryanodine receptor. Biochemical Society Journal (2004) Vol. 380, 561-569.
  • Antonio G. Catro, Margaret Neighbors, Stephen D. Hurst, Francesca Zonin, Regina A. Silva, Erin Murphy, Yong-Jun Liu, and Anne O’Garra. “Anti-Interleukin 10 Receptor Monoclonal Antibody Is an Adjuvant for T Helper Cell Type 1 Responses to Soluble Antigen Only in the Presence of Lipopolysaccharide.” The Journal of Experimental Medicine. 27 May 2007.
  • Silvia I. Garcia, Azucena L. Alvarez, Patricia I. Porto, Victoria M. Garfunkel, Sammuel Finkielman and Carlos J. Pirola. “Antisense Inhibition of Thyrotropin-Releasing Hormone Reduces Arterial Blood Pressure in Spontaneously Hypertensive Rats.” Journal of the American Heart Association, 2001.
  • James S. Gibbs, Daniela malide, Felicita Hornung, Jack R. Bennink, and Jonathan W. Yewdell. “The influenza A Virus PB1-F2 Protein Targets the Inner Mitochondrial Membrane via a Predicted Basic Amphipathis Helix That disrupts Mitochondrial Function.” Journal of Virology, July 2003, p. 7214-7224.
  • Susana Sarnago, Ramon Roca, Antonio de Blasi, Alfonso Valencia, Federico Mayor, Jr., and Cristina Murga. “Involvement of Intramolecular Interactions in the Regulation of G Protein-Coupled Receptor Kinase 2.” Molecular Pharmacology. Vol. 64, p. 629-639, 2003.
  • Theresa M. Geiman, Umesh T. Sankpal, Andrea K. Robertson, Yue Chen, Manjari mazumdar, Jason T. Heale, John A. Schmiesing, Wankee Kim, Kyoko Yokomori, Yingming Zhao and Keith D. Robertson. “Isolation and characterization of a novel DNA methyltransferase complex linking DNMT3B with components of the mitotic chromosome condensation machinery.” Nucleic Acids Research, 2004, vol. 32, No. 9, p. 2716-2729.
  • Anuradha Mehta, Michael T. Kinter, Nicholas E. Sherman, and Donna M. Driscoll. “Molecular Cloning of Apobec-1 Complementation Factor, a Novel RNA-Binding Protein Involved in the Editing of Apolipoprotein B mRNA.” Molecular and Cellular Biology, Mar. 2000, p. 1846-1854.
  • Sarah E. F. D’Orazio, Marisela Velasquez, Nadia R. Roan, Olaia Naveiras-Torres, and Michael N. Starnbach. “The Listeria monocytogenes lemA Gene Product Is Not Required for Intracellular Infection of To Activate fMIGWII-Specific T Cells.” Infection and Immunity, Dec. 2003, p. 6721-6727.
  • Libuse A. Bobek and Hongsa Situ. “MUC7 20-Mer: Investigation of Antimicrobial Activity, Secondary Structure, and Possible Mechanism of Antifungal Action.” Antimicrobial Agents and Chemotherapy, Feb. 2003, p. 643-652.
  • Feng Qian, Sacha Gnjatic, Elke Jager, Darren Santiago, Achim Jungbluth, Cathy Grande, Sally Schneider, Bernadette Keitz, Deborah Driscoll, Gerd Ritter, Shashikant Lele, Ashwani Sood, Lloyd J. Old, and Kunle Odunsi. “Th1/Th2 CD4+ T cell reponses against NY-EXO-1 in HLA-DPB1*0401/0402 patients with epithelial ovarian cancer.” Cancer Immunity, Vol. 4, p. 12 (3 November 2004).
  • Ji Hyung Chung, Eun Kyoung Im, Hyun-Young Park, Jun Hye Kwon, Seahyoung Lee, jaewon Oh, Ki-Chul Hwang, Jong Ho Lee, and Yangsoo Jang. “A novel uracil-DNA glycosylase family related to the helix-hairpin-helix DNA glycosylase superfamily.” Nucleic Acids Research, 2003, Vol. 31, No. 8, p. 2045-2055.
  • Olga I. Stenina, Earl J. Poptic, and Paul E. DiCorleto. “Thrombin activates a Y box-binding protein (DNA-binding protein B) in endothelial cells.” The Journal of Clinical Investigation, August 2000, Vol. 106, No. 4.
  • Hung T. Khong and Steven A. Rosenberg. “The Waardenburg Syndrome Type 4 Gene, SOX10, Is a Novel Tumor-associated Antigen Identified in a Patient with a Dramatic Response to Immunotherapy.” Cancer Research 62, p. 3020-3023, June 1, 2002.
  • Alan K. Meeker, Wesley R. Gage, Jessica L. Hicks, Inpakala Simon, Jonathan R. Coffman, Elizabeth A. Platz, Gerrun E. March, and Angelo M. De Marzo. “Telomere Length Assessment in Human Archival Tissues Combined Telomere Fluorescence in Situ Hybridization and Immunostaining.” American Journal of Pathology, Vol. 160, No. 4, April 2002.
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Bio-Synthesis,_Inc.&oldid=342781052"